Commentary|Videos|June 19, 2025

Recent Shifts in the Management of Lower-Risk MDS

Author(s)Guillermo Garcia-Manero, MD

Fact checked by: Chris Ryan

Guillermo Garcia-Manero, MD, highlights recent shifts in the lower-risk myelodysplastic syndrome treatment paradigm.

Episodes in this series

Guillermo Garcia-Manero, MD, highlights recent shifts in the lower-risk myelodysplastic syndrome treatment paradigm.

EP. 1 Recent Shifts in the Management of Lower-Risk MDS

Guillermo Garcia-Manero, MD, discusses OS data from the COMMANDS trial for luspatercept in ESA-naive, lower-risk MDS.

EP. 2 OS Data From COMMANDS for Luspatercept in ESA-Naive, Lower-Risk MDS

Guillermo Garcia-Manero, MD, highlights clinical trial findings and real-world data for luspatercept in ESA-naive, lower-risk MDS.

EP. 3 How Data Are Defining the Role of Luspatercept in ESA-Naive, Lower-Risk MDS

Guillermo Garcia-Manero, MD, discusses the integration of luspatercept into real-world practice in ESA-naive, lower-risk MDS.

EP. 4 Integrating Luspatercept Into Clinical Practice and Community Settings in ESA-Naive Lower-Risk MDS

Guillermo Garcia-Manero, MD, discusses second-line treatment decision-making in lower-risk MDS.

EP. 5 Navigating Second-Line Treatment Decisions in Lower-Risk MDS

Guillermo Garcia-Manero, MD, discusses ongoing research to watch in MDS.

EP. 6 Key Areas of Ongoing Research in MDS

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

Image Credit: © Tongpoon - stock.adobe.com

November 9th, 2026

FDA Flashback: Hematologic Cancer Decisions and News From October 2026

Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.

Trending on OncLive

FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC

Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer

Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer

CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition

NDA Submission Completed for Zipalertinib Plus Chemotherapy in Frontline EGFR Exon 20 Insertion–Positive NSCLC